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given. The carbidopa doses of 20 and 50 mg were ineffective. Carbidopa induced the enhancement of serum prolactin at a later time and over a longer time span than benserazide. The effect on serum prolactin is dose dependent for both drugs. The hyperprolactinaemia obtained with 250 mg of carbidopa and with 125 mg of benserazide is significantly larger in women than in age matched men. The observed prolactin increase fits with the hypothesis that a diminution of the inhibitory effect of dopamine at the pituitary and/or at the median eminence levels may occur in connection to the pharmacologically impaired monoamine synthesis. An effect of serotonin cannot, however, be excluded.
A considerable amount of evidence has been ac¬ cumulated indicating that dopamine (DA) is a neurotransmitter capable of exerting an inhibitory effect on the secretion of prolactin by the pituitary, acting directly on the gland or by mechanisms involving the central nervous system (Müller et al. 1977, for review of the literature).
Inhibitors of the aromatic aminoacids decarbox¬ ylase (AADC) The administration of carbidopa (Brown et al. 1976 ) and of benserazide (Pontiroli et al. 1977) to humans was followed by an increase of serum prolactin. The phenomenon was interpreted as depending on a decreased availability of DA in the nerve terminals of the outer median eminence and the pituitary that are exposed to the effect of the drugs, being both unprotected by the blood-brain barrier (Weindl & Joynt 1972) .
In these conditions the inhibitory action of DA on prolactin secretion is impaired.
In the present paper the effect of the acute 
